Artelo Biosciences gets U.S. patent allowance for ART27.13 drug

Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the intended commercial formulation of its investigational drug ART27.13, according to a press release.

The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol, including the company's intended commercial formulation. The patent protection is expected to extend through 2041.

ART27.13 is a peripherally selective cannabinoid agonist currently being evaluated in two Phase 2 studies: the CAReS trial for cancer-related anorexia and the DREAM study in patients with glaucoma or ocular hypertension.

Interim Phase 2 data from the CAReS trial showed that patients titrated to the highest ART27.13 dose of 1,300 µg achieved an average weight gain of 6% over 12 weeks, while patients on placebo lost an additional approximately 5%. The drug was well tolerated in Phase 1 and showed early signs of stabilizing or reversing weight loss in more than 60% of participants.

The DREAM study, an investigator-led trial funded by Glaucoma UK and the HSC R&D Division, is evaluating ART27.13 as a once-daily oral treatment to reduce intraocular pressure. Initial results are anticipated in the fourth quarter of this year.

"This U.S. Notice of Allowance and near-term expectation of the issuance of the patent further strengthens the intellectual property foundation supporting ART27.13 and its long-term development potential," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.

ART27.13 was initially developed by AstraZeneca and has been evaluated in seven clinical studies involving more than 280 participants. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome.

You May Also Be Interested In

• Intelligent Bio Solutions reports 98% accuracy in drug screening study
• Agencia awards $65M-$75M MEP contracts for Indonesia data center
• aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept